Cloudscreen

What Cloudscreen does

Cloudscreen is an AI-powered drug repurposing technology platform that uses artificial intelligence to accelerate the identification of new therapeutic applications for existing pharmaceutical compounds. The company's core technology targets the drug repurposing workflow — applying AI to match known drug molecules with new disease targets — addressing demand from pharmaceutical companies and healthcare providers for faster, lower-cost treatment development and precision medicine applications. As a standalone asset it operated with limited publicly disclosed footprint, headquartered under a Greek domain (cloudscreen.gr), with no disclosed headcount, patents, certifications, or named customers in the source material.

In 2025, Cloudscreen was acquired by Cosmos Health, a diversified healthcare company spanning pharmaceuticals, nutraceuticals, and healthcare services. The acquisition is part of Cosmos Health's strategic consolidation in the AI drug repurposing sector — a market projected to grow from $0.87B in 2024 to $2.19B by 2029 at a 20.2% CAGR. Post-acquisition, Cloudscreen's technology is being integrated alongside ZipDoctor within the Cosmos Health platform to enable patient-facing services with recurring engagement potential, moving the parent platform beyond product-only offerings. The revenue model is described as subscription/recurring through technology licensing and integration, with go-to-market executed via enterprise field sales to pharmaceutical and healthcare customers. Specific pricing, contract terms, and Cloudscreen-attributable revenue figures are not publicly disclosed; the only consolidated signal is Cosmos Health's record quarterly revenue exceeding $17 million in Q4 2025, of which Cloudscreen is one contributing asset among several.

Name

Cloudscreen

Legal name

Cloudscreen

Website

https://cloudscreen.gr

Company type

Private

Operating status

Acquired

Short description

Cloudscreen is an AI-powered drug repurposing technology platform acquired by Cosmos Health in 2025. It serves pharmaceutical companies and healthcare providers seeking AI-driven acceleration of treatment discovery and precision medicine, and is being integrated alongside ZipDoctor into Cosmos Health's diversified healthcare platform.

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Technology Licensing/Integration: Cloudscreen's AI drug repurposing technology is integrated into Cosmos Health's platform following acquisition, contributing to the company's record quarterly revenue exceeding $17 million and expanding gross profit margins as scale benefits take effect.

Go-to-market motion1 record

Core offering

Cloudscreen is an AI-powered drug repurposing platform that uses artificial intelligence to accelerate treatment discovery by matching existing compounds with new therapeutic indications. Following its acquisition by Cosmos Health, the platform is being integrated to support patient-facing services with recurring engagement potential alongside ZipDoctor, enabling precision medicine and personalized therapies within a diversified healthcare ecosystem spanning pharmaceuticals, nutraceuticals, and healthcare services.

Product overview

Cloudscreen is a healthcare technology platform acquired by Cosmos Health as part of its diversified healthcare model spanning pharmaceuticals, nutraceuticals, and healthcare services. The platform is being integrated with other acquired assets including ZipDoctor to expand beyond product-only offerings toward patient-facing services with recurring engagement potential.

Differentiator

Problem solved

Functional benefit

Products and services

• Cloudscreen AI Drug Repurposing Platform An AI-powered drug repurposing platform that uses artificial intelligence to accelerate treatment discovery by matching existing compounds with new therapeutic indications. It is targeted at pharmaceutical companies and healthcare providers seeking to enable precision medicine and personalized therapies within an integrated healthcare ecosystem.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Cosmos HealthcoreOthersCosmos Health acquired Cloudscreen as part of strategic consolidation in the AI drug repurposing sector. The acquisition positions Cloudscreen within Cosmos Health's diversified healthcare model spanning pharmaceuticals, nutraceuticals, and healthcare services. Cloudscreen's integration alongside ZipDoctor enables the platform to move toward patient-facing services with recurring engagement potential.

Scale indicators2 records

Recent moves3 records

Expansion highlights4 records

Direct peers

• Insilico Medicine: AI-driven drug discovery and repurposing platform using generative AI and deep learning to identify novel and repurposed therapeutic candidates. Directly comparable to Cloudscreen as a pure-play AI drug repurposing company targeting pharma customers.
• Recursion Pharmaceuticals: Combines high-throughput biology with AI/ML to discover and develop drugs at scale. Comparable as a publicly listed AI drug discovery platform with overlapping pharma customer base.
• Benevolent AI: AI-driven drug discovery company focused on accelerating and improving the drug development process, including repurposing. Closely comparable in target customers (pharma) and AI-enabled repurposing approach.
• Exscientia: AI-driven precision medicine company focused on faster drug discovery and development using AI-designed molecules. Directly comparable in business model and pharma customer orientation.
• Atomwise: Uses AI (AtomNet) for small-molecule drug discovery and hit identification, with significant pharma partnerships. Directly comparable as an AI-first platform selling into pharmaceutical R&D buyers.

Emerging players

• Healx: AI-driven drug repurposing company focused on rare diseases, using machine learning to identify new indications for existing drugs. Comparable as an emerging AI repurposing specialist with narrower therapeutic focus.
• Owkin: AI platform for healthcare and biopharma that applies machine learning to clinical and biomedical data for drug discovery and development. Comparable as an AI-healthcare platform serving pharma with overlapping technology and customers.

Broad incumbents

• Schrödinger: Established computational chemistry and molecular simulation platform used by pharma for drug discovery. Comparable as a broader, more established player in AI-enabled drug discovery serving similar pharmaceutical buyers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cloudscreen